All In Biotech

Drug Trial Radar · NCT07858344

Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Jan 18, 2024

Primary completion

Dec 27, 2024

Study completion Jan 3, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP). The main questions it aims to answer are: * Is YJ001 spray effective for patients with diabetic peripheral neuropathic pain(DPNP)? * The optimal effective dose of YJ001 spray for patients with diabetic peripheral neuropathic pain(DPNP). * Is YJ001 spray safe for patients with diabetic peripheral neuropathic pain(DPNP)? Researchers will divide YJ001 spray into three different doses of YJ001 spray and compare it with a placebo (a substance that looks similar but does not contain medication) to observe whether YJ001 spray can effectively treat diabetic peripheral neuropathic pain and to determine the optimal effective dose. Participants will: * Apply spray topically to both feet twice daily, with six sprays per foot at each administration.Attend scheduled study visits at baseline and weeks 1, 2, 4, 8, and 12, followed by a visit 1 week after Treatment termination. * Record their symptoms and the number of times they use the spray.

Conditions

  • Diabetic Peripheral Neuropathic Pain (DPNP)

Interventions

  • YJ001 spray simulatorDrug

    YJ001 spray 0mg/ml,apply spray to both feet 0mg each time,twice daily, with six sprays per foot.

  • YJ001 Spray 240 mg/dayDrug

    YJ001 spray 50mg/ml,apply spray to both feet 120mg each time,twice daily, with six sprays per foot.

  • YJ001 Spray 480 mg/dayDrug

    YJ001 spray 100mg/ml,apply spray to both feet 240mg each time,twice daily, with six sprays per foot.

  • YJ001 Spray 960 mg/dayDrug

    YJ001 spray 200mg/ml,apply spray to both feet 480mg each time,twice daily, with six sprays per foot

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.Time frame: baseline and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Haidian District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.